BioMark Diagnostics Inc.
BUX
Rang in aandelen
#26637
BioMark Diagnostics Inc. is an oncology specialist, developing advanced... BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Aandeelprijs
$0.33433516
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$35.60M
Verandering (1 dag)
-3.08%
Verandering (1 jaar)
39.31%
Land
CA
Handel BioMark Diagnostics Inc. (BUX)
Categorie
Healthcare
Koersgeschiedenis voor BioMark Diagnostics Inc. (BUX)
Hoogste slotkoers: $0.38 op 2026-10-01
Laagste slotkoers: $0.35 op 2015-03-01
Laagste slotkoers: $0.35 op 2015-03-01
Koersgeschiedenis van BioMark Diagnostics Inc. van 2015 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 6.88% |
| 2025 | 136.71% |
| 2024 | -19.87% |
| 2023 | 29.58% |
| 2022 | -34.72% |
| 2021 | 122.09% |
| 2020 | -51.07% |
| 2019 | 376.19% |
| 2018 | -44.93% |
| 2017 | -9.77% |
| 2016 | -22.98% |
| 2015 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $177.93 | 21.98% |
US
|
